ABL Diagnostics and CDL Pharma have secured a multi-year contract with a European pharmaceutical company for services related to neurodegenerative diseases, potentially worth up to €2.7 million through 2031. The agreement, signed by ABL Diagnostics for services operated by CDL Pharma, includes an initial payment exceeding €100,000 and is part of an international clinical program involving 30 centers across 11 countries in North America, Europe, and Asia.

The contract enhances the visibility of future revenue over multiple financial years and underscores the group's capability to support global multicenter studies. Revenue will be recognized progressively based on service performance and remains contingent on the effective progress of the clinical program. The partnership illustrates the progressive development of value-added services in international clinical research.

Scope of Services

Under the agreement, CDL Pharma will deliver specialized services including the operational management of international clinical trials, logistics and transportation of biological samples, design and management of sampling kits, cryogenic storage, and biomarker analysis. ABL Diagnostics acts as the distributor of these services to the end customer.

Contract Details

Mohamed Errafyqy, Sales and Operations Manager at ABL Diagnostics, commented that the contract illustrates the company's ability to support complex international clinical programs and deliver integrated service offerings. The neurodegenerative diseases market is supported by structural trends such as aging populations and new therapeutic approaches, with industry reports suggesting the market could reach approximately USD 88 billion by 2030–2031. However, these estimates are based on uncertain growth assumptions and do not constitute a prediction of actual market developments or ABL Diagnostics' potential share.

ABL Diagnostics submitted a bid on June 9, 2026, to acquire the business and assets of Texcell France, a company specializing in viral safety testing, immunology, and R&D services for biopharmaceutical products. The target company is currently subject to judicial reorganization proceedings before the Commercial Court of Évry. This strategic move by ABL Diagnostics aims to assess external growth opportunities complementary to its existing portfolio of molecular diagnostic solutions, healthcare software, and clinical sample management.

The proposed acquisition is based on Article L. 642-1 of the French Commercial Code. However, the transaction remains contingent upon the decision of the Commercial Court of Évry. At this stage, there is no certainty regarding the outcome of these insolvency proceedings. ABL Diagnostics stated it will keep the market informed of any significant developments in accordance with applicable regulatory obligations.

ABL Diagnostics specializes in innovative molecular biology tests and global solutions, including molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand. The company markets its products globally through its own sales team and a network of exclusive distributors. Its customer base includes academic clinical pathology laboratories, private reference laboratories, and researchers.

The company has an expanding portfolio of microbiology products, covering areas such as HIV drug resistance testing, SARS-CoV-2, Tuberculosis, Hepatitis B and C detection solutions, and microbiome analyses. Additionally, ABL Diagnostics offers integrated solutions like real-time syndromic PCR tests, the Nadis® Patient Medical Record used in over 200 hospitals in France, and MediaChek® Clinical Sample Collection Kits.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. Headquartered in Woippy, ABL Diagnostics is a public limited company listed on compartment B of the regulated market of Euronext in Paris.